Annual report 2025

The 2025 Annual Report highlights Vaccines Europe’s work to keep immunisation high on the political agenda, including:

• The fourth annual Pipeline Review, showcasing 91 vaccine and monoclonal antibody candidates currently in clinical development by Vaccines Europe member companies.
• Our work supporting the implementation of the EU Health Technology Assessment (HTA) Regulation for vaccines.
• Continued efforts to demonstrate the value of immunisation beyond infectious disease prevention, including advancing the EU Safe Hearts Plan to address cardiovascular disease (CVD).
• Our advocacy to reinforce the message that immunisation is an investment in healthier societies and more resilient economies.
• Our work on the Biotech Act, akey opportunity to strengthen Europe’s biotech competitiveness and attract high-value research and development.
• Strengthening Vaccines Today to ensure it remains a trusted, fit-for-purpose platform in an era of increasing misinformation.
• Our events, partnerships, and collaborations with key stakeholders across the European vaccine ecosystem.

Annual report 2024

The 2024 annual report showcases our work in line with our mission to foster innovation and value recognition of lifecourse immunisation in Europe to protect people against evolving health challenges. Key highlights include:

• The report on the economic value of prevention by The European House – Ambrosetti, in collaboration with IFPMA, which emphasises that immunisation should be viewed as an investment, not a cost;
• Our paper on vaccine supply chain resilience, which summarises five ways that resilience of supply chains can be enhanced;
• The latest pipeline review of Vaccines Europe member companies, showing there are currently 98 vaccines in development across 12 different technology platforms;
• The article “Guiding Principles for Evaluating Vaccines in Joint Health Technology Assessment in the European Union” in the journal Value in Health, which puts forward 3 guiding principles to preparing for the EU HTA Regulation for vaccines;
• Our sustained investment in Vaccines Today underlining the importance of providing trusted and independent information on vaccines and vaccination, particularly in today’s context;
• Our events and collaborations with key vaccine stakeholders.

——————————————————————————————————————

Annual report 2023

Our annual report for 2023 highlights the work we have done across the vaccine ecosystem towards realising the full value of vaccination. The annual report highlights our initiatives from 2023, including the updated pipeline review of our member companies, the report on EU’s attractiveness for the vaccine industry, the importance of data for vaccine-preventable cancers, the role of vaccination in the fight against antimicrobial resistance, and our Manifesto for the next mandate, among others. The annual report also outlines key collaborations and partnerships with stakeholders across the vaccine ecosystem, as well as the expansion of the Vaccines Europe team.

We look forward to continuing our work with an evolved mission and strategy for the next EU mandate, for a healthy, innovative and prosperous Europe.

——————————————————————————————————————

Annual report 2022

As 2023 comes to a close and 2024 approaches, we are committed to continuing to work on every part of the vaccine ecosystem covering research & innovation, regulatory affairs, manufacturing and supply, market access and public policy, immunisation financing and vaccine acceptance.

The Vaccines Europe Annual Report highlights how the team has grown over the past 2 years with the addition of new team members and new or increased collaborations with key EU stakeholders. The report also reiterates Vaccines Europe’s position on key policy issues and support to key strategic initiatives. 

Our positive development is demonstrated through activities supporting Vaccines Europe’s strategic priorities of innovation, access and value. Our main focus in 2022 was on the prioritisation of adult immunisation policies in Europe as well as improving the attractiveness of the vaccines industry in the EU.